Activation of PPARgamma by pioglitazone does not attenuate left ventricular hypertrophy following aortic banding in rats.

Naunyn-Schmiedeberg's Archives of Pharmacology
Celine S WeissStefan E Hardt

Abstract

Sustained left ventricular hypertrophy (LVH) accelerates cardiac dysfunction and heart failure. Previous reports have suggested that activation of the peroxisome proliferator-activated receptor gamma (PPARgamma)-dependent pathway is involved in development of cardiac hypertrophy. Thiazolidinediones (TZDs) such as pioglitazone activate PPARgamma and are clinically used as antidiabetics. Given inconsistent reports regarding effects of TZDs on LVH, we examined in the present study the influence of pioglitazone on LVH in a rat model of aortic banding. Aortic banding was induced in rats by clipping the ascending aorta. Animals received pioglitazone (3 mg/kg/day) or placebo. Echocardiographic, hemodynamic, histological, and biochemical measurements were performed after 2 and 4 weeks. Pressure gradient was comparable between pioglitazone- and placebo-treated animals after 2 and 4 weeks. Left ventricular function was not different between the groups. In sham as well as in banded animals, LV/body weight ratio was increased in pioglitazone- as compared to placebo-treated animals after 2 and 4 weeks. Furthermore, an increase in myocyte size and atrial natriuretic factor was observed in pioglitazone- compared to placebo-treated animals 4 w...Continue Reading

References

Jul 25, 1997·The Journal of Biological Chemistry·L FajasJ Auwerx
May 20, 1998·The Journal of Clinical Endocrinology and Metabolism·J MinamikawaH Koshiyama
Dec 22, 1999·British Journal of Pharmacology·L C PickavanceJ P Wilding
Mar 1, 2000·British Journal of Pharmacology·D Bishop-Bailey
Aug 23, 2000·The Journal of Clinical Investigation·J M Olefsky
Dec 24, 2003·Laboratory Investigation; a Journal of Technical Methods and Pathology·Haruyasu ItoAkira Matsumori
Feb 6, 2004·Clinical and Experimental Pharmacology & Physiology·Kenji ArakawaAkira Saito
May 29, 2004·Trends in Pharmacological Sciences·Shamina M Rangwala, Mitchell A Lazar
Feb 1, 2005·European Journal of Pharmacology·David Bell, Barbara J McDermott
Jun 16, 2005·Proceedings of the National Academy of Sciences of the United States of America·Hui ZhangTianxin Yang
Aug 2, 2005·American Journal of Hypertension·Takeshi HorioYuhei Kawano
Sep 27, 2005·Diabetes/metabolism Research and Reviews·Rehan Qayyum, Peter Schulman
Jan 20, 2007·Methods and Findings in Experimental and Clinical Pharmacology·P Balakumar, M Singh
May 23, 2007·The New England Journal of Medicine·Steven E Nissen, Kathy Wolski
Sep 8, 2007·The Journal of Clinical Investigation·Ni-Huiping SonIra J Goldberg
Apr 29, 2009·Journal of Molecular and Cellular Cardiology·William T FestucciaYves Deshaies

❮ Previous
Next ❯

Citations

Apr 30, 2013·Naunyn-Schmiedeberg's Archives of Pharmacology·Cui-cui LuZhi-min Du
Dec 21, 2011·Cardiovascular Drugs and Therapy·Ting HeMan-Wen Jin
May 4, 2016·Basic Research in Cardiology·Tammy A ButterickEdward O McFalls
Nov 8, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Sebastian J BussStefan E Hardt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.